Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen H, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI.
Corcoran RB, et al. Among authors: parikh ar.
Clin Cancer Res. 2024 May 1;30(9):1739-1749. doi: 10.1158/1078-0432.CCR-23-3135.
Clin Cancer Res. 2024.
PMID: 38456660
Free PMC article.
Clinical Trial.